Centessa Pharmaceuticals (CNTA) Share-based Compensation (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Share-based Compensation data on file, last reported at $10.6 million in Q1 2026.

• Quarterly Share-based Compensation rose 34.02% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.6 million (up 1.11% YoY) and the FY2025 annual result came in at $31.0 million, down 7.7% from the prior year.
• Share-based Compensation rose to $10.6 million in Q1 2026 per CNTA's latest filing, from $7.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $10.6 million in Q1 2026 and bottomed at $5.6 million in Q2 2022.
• The 5-year median for Share-based Compensation is $7.6 million (2023), against an average of $7.6 million.
• The widest annual swing landed in 2022, when Share-based Compensation jumped 109.37%; it then slipped 14.89% in 2025.
• Tracing CNTA's Share-based Compensation over 5 years: stood at $6.6 million in 2022, then grew by 12.29% to $7.4 million in 2023, then increased by 12.09% to $8.3 million in 2024, then slipped by 4.71% to $7.9 million in 2025, then soared by 33.13% to $10.6 million in 2026.
• Per Business Quant, the three latest CNTA Share-based Compensation figures stand at $10.6 million (Q1 2026), $7.9 million (Q4 2025), and $7.2 million (Q3 2025).

Peer Comparison